Recent advancement in nanocarriers for oral vaccination.

Artif Cells Nanomed Biotechnol

a Department of Pharmaceutics, I.S.F. College of Pharmacy, Moga , India.

Published: June 2019

Non-invasive mucosal immune response plays an important role in controlling various infections through mucosal route. Therefore, the appropriate induction of effective immune response should be elicited after immunization. Currently, a lot of strategies have been investigated to enhance the mucosal immunity including microparticles, liposomes, virosomes, cochleates and aracheosomes. These carriers due to tunable and unique physicochemical properties offer the possibility for better antigen presentation by appropriate cells, being more effective to induce a comparable immune response. The objective of this review is to give an overview of novel strategies for the delivery of vaccines through the mucosal route.

Download full-text PDF

Source
http://dx.doi.org/10.1080/21691401.2018.1533842DOI Listing

Publication Analysis

Top Keywords

immune response
12
mucosal route
8
advancement nanocarriers
4
nanocarriers oral
4
oral vaccination
4
vaccination non-invasive
4
mucosal
4
non-invasive mucosal
4
mucosal immune
4
response plays
4

Similar Publications

Background: Epidemiological studies associate an increase in breast cancer risk, particularly triple-negative breast cancer (TNBC), with lack of breastfeeding. This is more prevalent in African American women, with significantly lower rate of breastfeeding compared to Caucasian women. Prolonged breastfeeding leads to gradual involution (GI), whereas short-term or lack of breastfeeding leads to abrupt involution (AI) of the breast.

View Article and Find Full Text PDF

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Exp Hematol Oncol

January 2025

Bone Marrow Transplantation Center of The First Affiliated Hospital Liangzhu Laboratory, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang, China.

Background: Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited.

Methods: This study aimed to evaluate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL between November 2020 and November 2023 (ChiCTR2100053871). Key endpoints included the adverse event incidence, overall survival (OS), and leukemia-free survival (LFS).

View Article and Find Full Text PDF

Enhancer RNA (eRNA) has emerged as a key player in cancer biology, influencing various aspects of tumor development and progression. In this study, we investigated the role of eRNAs in kidney renal clear cell carcinoma (KIRC), the most common subtype of renal cell carcinoma. Leveraging high-throughput sequencing data and bioinformatics analysis, we identified differentially expressed eRNAs in KIRC and constructed eRNA-centric regulatory networks.

View Article and Find Full Text PDF

Objectives: SOX10 is crucially implicated in various cancer, yet the regulatory role in pancreatic cancer (PC) remains enigmatic. Underlying molecular mechanisms of SOX10 in PC were explored in our study.

Methods: Relationships between SOX10 and immune landscape were estimated using bioinformatic approaches.

View Article and Find Full Text PDF

Association of pan-immune-inflammatory value with metabolic dysfunction-associated steatotic liver disease: findings from NHANES 2017-2020.

BMC Gastroenterol

January 2025

Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide. The pan-immune-inflammation value (PIV) has been proposed as a biomarker for assessing immune status and inflammation. There is currently no evidence regarding the effect of PIV on the risk of MASLD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!